Innovent, Eli Lilly sign drug deal
Innovent Biologics said it has reached an agreement with Eli Lilly to co-develop new oncology and immunology medicines. The deal includes USD 350 million upfront and up to USD 8.5 billion in milestone payments, with Innovent leading early development in China and Eli Lilly holding global rights outside Greater China.